This company no longer operates independently (acquired, merged, or ceased operations). This profile is retained for reference.
UK-based clinical-stage biotech founded in 2019 (rooted in the Beckley Foundation's psychedelic research) developing psychedelic medicines for treatment-resistant depression, alcohol use disorder and other conditions. Its lead asset BPL-003 is an intranasal synthetic formulation of 5-MeO-DMT (mebufotenin) that met primary and key secondary endpoints in a Phase 2b treatment-resistant depression trial and holds FDA Breakthrough Therapy designation. In November 2025 Beckley Psytech was acquired by atai Life Sciences in an all-share merger, forming AtaiBeckley.
Beckley Psytech News 19 articles
- atai and Beckley Psytech complete combination to form AtaiBeckley
- FDA grants Breakthrough Therapy designation to BPL-003 for treatment-resistant depression
- atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
- Atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
- atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
- Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
- atai Life Sciences Applauds Breakthrough in Depression Treatment with Beckley Psytech’s DMT Study
- Beckley Psytech announces positive initial data from Phase IIa study of novel 5-MeO-DMT formulation BPL-003 for Treatment Resistant Depression
- atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
- Cedar Clinical Research Selected as Clinical Research Site for Beckley Psytech’s Phase 2b Study
- First Patient Dosed in Beckley Psytech’s International Phase IIb Study of BPL-003, a Novel Synthetic Intranasal Formulation of 5-MeO-DMT, for Treatment Resistant Depression (TRD)
- First Patient Dosed in Beckley Psytech’s Phase IIa Study of BPL-003 for Treatment Resistant Depression
- Beckley Psytech receives FDA Investigational New Drug (IND) approval for Phase IIb study of BPL-003, a novel synthetic formulation of 5-MeO-DMT (Mebufotenin)
- Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003, a Novel Benzoate Formulation of 5-MeO-DMT, for Treatment Resistant Depression
- Beckley Psytech Successfully Completes Phase I Clinical Study of Lead Candidate BPL-003, a Novel Benzoate Formulation Of 5-MeO-DMT
- Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin
- Beckley Psytech to Attend and Present at the Jefferies London Healthcare Conference – November 15-17, 2022
- Beckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics Limited
- Beckley Psytech completes oversubscribed $80m fundraise to develop portfolio of psychedelic medicine breakthroughs